International Myeloma Foundation Responds to ICER Report

The International Myeloma Foundation (IMF) recently spoke out against the Institute for Clinical and Economic Review’s (ICER) report on the value of myeloma drugs. Find out what IMF had to say here. (Source: Journal of Clinical Pathways, 5/26/16)

You might also be interested in:

Journal Interviews Co-Authors of ASCO Pathway Report April 4, 2018
ICER Releases Report on Plaque Psoriasis Treatments April 28, 2018
New ICER Report Reviews Elagolix for Endometriosis May 5, 2018
ICER Using New Economic Modeling Platform for Value Assessment August 24, 2018
ICER Releases Draft Evidence Report on CFTR Modulator… March 16, 2018
ICER Releases Draft Evidence Report on CGRP Inhibitors for… April 12, 2018
ICER Posts Draft Scoping Document on Medication-Assisted… April 28, 2018